Novo Nordisk acquires Zaltenibart from Omeros for up to $2.1 billion and strengthens its position in the treatment of rare blood and kidney diseases

Novo Nordisk (ii) acquires a promising drug from Omeros, which is being developed for the treatment of rare blood and kidney diseases. The biopharmaceutical company listed on the Nasdaq could receive up to $2.1 billion as a result. Details of the Acquisition and Licensing Agreement Under the purchase and licensing agreement, Novo Nordisk obtains the exclusive global rights to develop and market Zaltenibart. The drug has already shown positive study results in treating an autoimmune blood disorder and also offers potential for the treatment of...